SGLT2 inhibitors for advanced kidney disease
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced chronic kidney disease with very low kidney function (eGFR less than 20).
- You are not on dialysis.
- You do not have a genetic kidney disease called ADPKD.
- You do not have type 1 diabetes.
- You are not already taking an SGLT2 inhibitor medication.
- You have not had ketoacidosis in the last 3 months, and are not allergic to SGLT2 inhibitors.
- You do not have significant liver disease, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This study tests whether the drug Henagliflozin can protect the kidneys in people with advanced chronic kidney disease (CKD) who are not yet on dialysis. It may help slow kidney decline and delay the need for dialysis.
This trial tests a medication called SGLT2 inhibitor (a type of diabetes drug that may also help protect the kidneys) in children with chronic kidney disease. It aims to see if the drug is safe and easy to use in children ages 2–18 with moderate to severe kidney problems.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
Hear when a new Chronic Kidney Disease Stage 5 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.